[Skip to Content]
[Skip to Content Landing]
Views 8,022
Citations 0
Viewpoint
June 5, 2018

Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs

Author Affiliations
  • 1Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia
  • 2Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia
JAMA. 2018;319(21):2167-2168. doi:10.1001/jama.2018.3414

Spending on cancer drugs in the United States has increased substantially over the past 5 years, from $26 billion in 2012 to more than $45 billion in 2016.1 Targeted cancer drugs, including small molecules, monoclonal antibodies, and other therapies based on genomic and related analyses, contributed 60% of this spending growth.2 One estimate suggests that by 2021, cancer drugs will comprise one-quarter of the US late-stage pharmaceutical research and development pipeline, and 87% of these products will be targeted agents.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×